Table 2 Multivariate analyses examining treatment exposure type predicting biomarkers of aging parameters at final visit (TF) adjusting for age, race, BMI, and years from treatment
From: Biomarkers of aging associated with past treatments in breast cancer survivors
WBC DNA damage (high damage vs. low) | PBMC telomerase (deciles) | PBMC telomere length (T/S) | |||||||
|---|---|---|---|---|---|---|---|---|---|
Predictor | β(SE)a | OR(95% CI)b | P-value | β(SE) | Betac | P-value | β(SE) | Beta | P-value |
Covariates in the model | |||||||||
Age (years) | 0.15(.05) | 1.16(1.06, 1.28) | .002 | −0.09(.04) | −0.23 | .04 | −0.004(.004) | −0.11 | .32 |
Race (White = 1) | 1.14(1.23) | 3.14(0.35, 28.59) | .31 | 0.05(.91) | 0.007 | .96 | −0.11(.08) | −0.17 | .16 |
Body mass index (kg/m2) | 0.007(.06) | 1.01(0.89, 1.14) | .92 | −0.04(.07) | −0.07 | .54 | −0.01(.006) | −0.23 | .04 |
Years from treatment | 1.49(.47) | 4.44(1.77, 11.16) | .002 | −0.17(.48) | −0.04 | .73 | −0.05(.05) | −0.11 | .32 |
Treatment exposure | |||||||||
Chemotherapy and/or radiationd | 2.92(1.26) | 18.49(1.56, 218.9) | .02 | −1.93(.83) | −0.25 | .02 | 0.07(.08) | 0.09 | .39 |
